Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2009

View Archived Issues

AlphaRx and Venturepharm sign agreement for drug development center in China

Laboratory Corporation acquires Monogram Biosciences pursuant to cash tender offer

New inhibitors of the MDM2-p53 interaction reported by Roche as oncolytics

Anesiva and Arcion Therapeutics sign definitive merger agreement

FDA requests stronger cancer warnings in prescribing information for TNF blockers

Radius reports results from phase II clinical trial of BA-058 in osteoporosis

Rib-X reports results from phase II clinical trial of radezolid in CAP

European Commission approves Novartis' Afinitor for RCC patients

Acura submits briefing package to FDA for Acurox NDA in moderate to severe pain

MJFF grants funding to Ceregene for long-term testing in phase II trial of CERE-120

ARRY-520 shows similar preclinical activity to paclitaxel without NF-kappaB and cytokine activation

Phase I/II data support clinical activity of icotinib in later stage non-small cell lung cancer

Neurological recovery induced by fenofibrate/simvastatin in rat model of traumatic brain injury

Rosiglitazone prevents stroke-induced inflammation in mouse model of type 2 diabetes

Early phase I/II data suggest safety and immunogenicity of HIV DNA vaccine in healthy subjects

Soluble epoxide hydrolase inhibitors described by Arete Therapeutics for vascular conditions

French researchers claim novel anticancer compounds

Amgen presents PI3Kalpha inhibitors for cancer treatment

Dipeptidyl peptidase IV inhibitors in early development at LG Life Sciences

Genelabs and Novartis disclose novel compounds for treating hepatitis C viral infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...